DIFLUNISAL

Post-LOE

Teva

ANDAORALTABLET

Approved

Jul 1992

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DIFLUNISAL by Teva is clinical pharmacology action dolobid is a non-steroidal drug with analgesic, anti-inflammatory and antipyretic properties. First approved in 1992.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Action Dolobid is a non-steroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance, and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic…

Worked on DIFLUNISAL at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DIFLUNISAL

Mechanism of Action

Indications

Clinical Trials (1)